Atricure, INC 8-K filings

AtriCure announced second quarter 2026 financial results, showcasing a 12.8% year-over-year revenue increase to $153.6 million and a significant improvement in profitability.

AtriCure, Inc. stockholders approved amendments to the 2023 Stock Incentive Plan and 2018 Employee Stock Purchase Plan, increasing authorized shares.

AtriCure announced first quarter 2026 financial results, showcasing a 14.3% year-over-year revenue increase to $141.2 million and improved profitability with net income of $0.1 million.

AtriCure, Inc. extended its credit facility by three years, reduced interest rates, and reported strong preliminary 2025 financial results with optimistic 2026 guidance.

AtriCure, Inc. reported strong third quarter 2025 financial results with worldwide revenue increasing 15.8% year-over-year and raised its full-year financial outlook.

AtriCure, Inc. reported strong third quarter 2025 financial results with significant revenue growth and improved profitability, leading to an increased full-year financial outlook.

AtriCure, Inc. announced robust second quarter 2025 financial results, including significant revenue growth and improved profitability, leading to an upward revision of its full-year financial guidance.

AtriCure's stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing the number of shares available for issuance.

AtriCure announces a 13.6% year-over-year revenue increase in Q1 2025, driven by new product launches and global adoption of its therapies.

AtriCure outlines its strategic vision to reach $1 billion in revenue by 2030, focusing on expanding its market presence, innovating new therapies, and improving patient outcomes in the treatment of Afib and pain management.

AtriCure announces a 16.6% increase in Q4 worldwide revenue and a 16.5% increase in full year 2024 revenue, fueled by product launches and market penetration.

AtriCure reported preliminary 2024 financial results showing 17% revenue growth and provided a positive 2025 outlook with projected revenue between $517 million and $527 million.

AtriCure announced a 17.9% year-over-year increase in worldwide revenue for the third quarter of 2024, reaching $115.9 million, alongside positive cash flow generation.

AtriCure's second quarter results show a 15.2% year-over-year revenue increase, driven by strong growth in pain management and international markets, and positive cash flow generation.

AtriCure's stockholders approved an increase in shares available under the 2023 Stock Incentive Plan and an amendment to limit officer liability at the 2024 Annual Meeting.

AtriCure reported a 16.4% year-over-year increase in worldwide revenue for the first quarter of 2024, reaching $108.9 million.

AtriCure, Inc. has amended its previous 8-K filing to announce Shlomi Nachman's appointment to the Strategy Committee and Compliance, Quality and Risk Committee, effective February 22, 2024.

AtriCure's full-year 2023 results show a 20.8% increase in worldwide revenue and a significant improvement in adjusted EBITDA, signaling strong growth and progress towards sustained profitability.